Pulmonary Arterial Hypertension (PAH) – Market Access and Reimbursement Insights Report – 2025
- Published Date : February 17, 2025
- Updated On : October 21, 2025
- Pages : 51
Pulmonary Arterial Hypertension (PAH) Market Access and Reimbursement Insights
Thelansis’s “Pulmonary Arterial Hypertension (PAH) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Pulmonary Arterial Hypertension (PAH) Overview
Pulmonary arterial hypertension (PAH) is a progressive and chronic condition marked by antiproliferative changes in the pulmonary arterioles, resulting in endothelial and smooth muscle proliferation and dysfunction, inflammation, and the formation of blood clots. PAH is primarily caused by remodeling of pulmonary arteries, narrowing, and obstructing the smallest arteries. This increased resistance in the pulmonary circulation results in elevated pressure within the right ventricle. Specific gene mutations, including BMPR2 (2q33), ACVRL1 (12q13), Endoglin (9q34), CAV1 (7q31), KCNK3 (2p23), Smad9 (13q12), and TBX4 (17q21), have been associated with heritable PAH. Most cases of PAH typically develop in adults, with occasional occurrences in children. Women are twice as likely as men to be affected by this condition. Initial symptoms include shortness of breath, fainting, chest discomfort, palpitations, and swelling in the lower extremities.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
Deliverables format:
- PowerPoint presentation
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
- Market access and reimbursement for current therapies
- Coverage on plans
- Market access restrictions
- Rebates and contracting
- Factors influencing formulary access
- HEOR requirements and influence, etc.
- Expected market access and reimbursement for key emerging therapies
- Level of awareness
- Anticipated coverage on plans
- Factors that would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors driving and limiting brand use
- Best and worst performers on market access, etc.
- Evolving environment
- Payer expectations from emerging therapies
- New policies and their expected impact, etc.
- Advise to drug manufacturers and developers
Pulmonary Arterial Hypertension (PAH) Market Access and Reimbursement Insights
Thelansis’s “Pulmonary Arterial Hypertension (PAH) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Pulmonary Arterial Hypertension (PAH) Overview
Pulmonary arterial hypertension (PAH) is a progressive and chronic condition marked by antiproliferative changes in the pulmonary arterioles, resulting in endothelial and smooth muscle proliferation and dysfunction, inflammation, and the formation of blood clots. PAH is primarily caused by remodeling of pulmonary arteries, narrowing, and obstructing the smallest arteries. This increased resistance in the pulmonary circulation results in elevated pressure within the right ventricle. Specific gene mutations, including BMPR2 (2q33), ACVRL1 (12q13), Endoglin (9q34), CAV1 (7q31), KCNK3 (2p23), Smad9 (13q12), and TBX4 (17q21), have been associated with heritable PAH. Most cases of PAH typically develop in adults, with occasional occurrences in children. Women are twice as likely as men to be affected by this condition. Initial symptoms include shortness of breath, fainting, chest discomfort, palpitations, and swelling in the lower extremities.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
Deliverables format:
- PowerPoint presentation
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
- Market access and reimbursement for current therapies
- Coverage on plans
- Market access restrictions
- Rebates and contracting
- Factors influencing formulary access
- HEOR requirements and influence, etc.
- Expected market access and reimbursement for key emerging therapies
- Level of awareness
- Anticipated coverage on plans
- Factors that would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors driving and limiting brand use
- Best and worst performers on market access, etc.
- Evolving environment
- Payer expectations from emerging therapies
- New policies and their expected impact, etc.
- Advise to drug manufacturers and developers
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)